AWaRe Benchmarking Tool Brings Antibiotic Stewardship Into Sharper Focus
A new medRxiv preprint proposes a way to measure hospital antibiotic use against the AWaRe framework with far greater precision. The study centers on a benchmarking tool applied to cross-sectional point prevalence survey data from 10 countries, a design that places antimicrobial stewardship in a comparative, operational setting rather than as an abstract policy goal.
The premise is straightforward and clinically important. Hospitals do not just need to know how much antibiotic therapy is being used; they need to know whether the mix is aligned with agents that should be Access-first, while Watch and Reserve agents remain appropriately constrained. In practice, antibiotic selection exerts pressure on resistance patterns long before clinicians can see the downstream consequences in their own wards.
Why AWaRe Benchmarking Matters at the Bedside
The AWaRe classification, used widely in stewardship programs, separates antibiotics into groups that reflect their relative public health risk and stewardship priority. Access agents are generally preferred for common infections when clinically appropriate. Watch agents deserve more restraint because of their higher resistance potential, and Reserve agents are intended for select situations when other options fail or are unsuitable. A hospital-level benchmarking tool built around this structure can expose whether prescribing drift is being driven by case mix, local habits, limited diagnostics, or entrenched routine use.
That question is especially relevant in cross-sectional point prevalence surveys, where antibiotic exposure is captured at a specific time across multiple settings. Such snapshots cannot answer every causal question, but they are useful for identifying patterns that a ward team, infection control group, or national program can act on quickly. In settings with limited stewardship infrastructure, even a relatively simple comparison of observed prescribing against an optimal pattern may help prioritize where intervention is most urgently needed.
The value of this approach lies in its practicality. Antibiotic stewardship programs often struggle with fragmented data, inconsistent denominators, and surveillance outputs that are too broad to guide local action. A benchmarking tool that can translate point prevalence survey data into interpretable estimates of antibiotic-use quality offers a more immediate route from measurement to policy.
From Counts to Stewardship Signals
The study’s framing suggests an effort to move beyond raw antibiotic volume. Total use alone can hide whether a hospital relies heavily on broad-spectrum Watch agents when narrower Access options would suffice, or whether Reserve drugs are creeping into routine practice. In antimicrobial stewardship, those details matter because selection pressure is not distributed evenly across drug classes. A hospital that substitutes broad-spectrum therapy for simpler regimens may see resistance emerge even if overall antibiotic volume appears stable.
A benchmarking system also raises a more disciplined comparison across countries. Point prevalence survey data gathered in 10 countries allow investigators to examine how prescribing patterns differ across health systems, not merely within one institution. Cross-country variation can reflect genuine differences in disease burden, but it can also expose supply constraints, guideline adherence gaps, or differences in diagnostic support. For policymakers, those distinctions are useful because they separate problems that require educational intervention from problems that need structural reform.
One sentence captures the clinical stakes plainly: stewardship cannot improve what it cannot measure.
What a Multicountry Tool Can Expose
A hospital antibiotic benchmark grounded in AWaRe can reveal several layers of risk. If Access use is low, clinicians may be defaulting to broader agents earlier than necessary. If Watch use dominates, resistance pressure may be rising even in facilities that believe their prescribing is conservative. If Reserve antibiotics begin to appear in routine prevalence data, the alert is no longer theoretical; it signals a potential erosion of last-line protection.
Because the study uses cross-sectional survey data, its value is likely strongest as a comparative instrument rather than a longitudinal outcomes analysis. That matters for interpretation. A prevalence survey can identify the shape of prescribing, but it cannot by itself prove why prescribing looks the way it does or whether one hospital’s mix is better because of its case mix, its formulary, or its stewardship culture. Still, benchmarking is often the first step toward accountability, especially in regions where formal antibiograms, pharmacy dashboards, or national surveillance systems are incomplete.
In a broader sense, the paper fits into a growing recognition that antibiotic stewardship needs standardized metrics that travel across settings. Clinicians, hospital pharmacists, microbiologists, and public health teams speak more clearly to each other when they are evaluating the same categories and the same denominators. AWaRe offers that shared language, and a benchmarking tool built around it could make the framework more usable at scale.
The key clinical question is not whether stewardship should happen. It is whether hospitals can see their own prescribing clearly enough to change it.
Limits Inherent to Snapshot Surveillance
Cross-sectional point prevalence surveys bring unavoidable constraints. They capture prescribing at one moment, which means seasonal variation, outbreaks, and changing admissions can all influence the picture. They also depend on the quality of the underlying data, including how indications are recorded and how antibiotics are classified. In multicountry work, differences in documentation and local practice can complicate comparisons even when the metric itself is standardized.
Those limitations do not erase the utility of the benchmark. They do, however, keep expectations grounded. A tool of this kind should be read as a stewardship dashboard, not as a definitive judgment on quality of care. Its real contribution is to identify where more detailed review is needed and to make antibiotic use visible in a form that can be acted on by clinicians and health system leaders.
For hospitals facing rising resistance pressure, that visibility is not optional. It is the starting point for any serious attempt to protect the drugs that still work.